BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of “Moderate Buy” from Analysts

BeiGene, Ltd. (NASDAQ:BGNE) has been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $241.21.

Several equities analysts have recently weighed in on BGNE shares. Bank of America reduced their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research report on Tuesday, July 9th. JMP Securities started coverage on BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target for the company. Citigroup lifted their price target on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. lifted their price target on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th.

Insider Buying and Selling

In related news, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $237.10, for a total transaction of $284,994.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, COO Xiaobin Wu sold 5,556 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Chan Henry Lee sold 1,202 shares of the company’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $237.10, for a total value of $284,994.20. The disclosure for this sale can be found here. Insiders sold a total of 23,904 shares of company stock worth $5,034,965 over the last ninety days. 7.43% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BeiGene

A number of hedge funds and other institutional investors have recently modified their holdings of BGNE. Capital International Investors boosted its holdings in shares of BeiGene by 11.5% in the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock worth $1,104,806,000 after purchasing an additional 727,556 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of BeiGene in the 2nd quarter worth about $54,412,000. M&G Plc purchased a new position in shares of BeiGene in the 1st quarter worth about $29,649,000. Goldman Sachs Group Inc. lifted its stake in shares of BeiGene by 175.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after acquiring an additional 136,458 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of BeiGene by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after acquiring an additional 117,905 shares during the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeiGene Stock Performance

Shares of BGNE opened at $222.60 on Friday. The firm has a market cap of $21.57 billion, a PE ratio of -29.41 and a beta of 0.62. The stock’s fifty day moving average price is $205.15 and its two-hundred day moving average price is $172.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. BeiGene has a 1 year low of $126.97 and a 1 year high of $248.16.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The business’s revenue was up 56.1% on a year-over-year basis. During the same period in the previous year, the company posted ($3.64) earnings per share. On average, equities research analysts forecast that BeiGene will post -5.07 EPS for the current year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.